Member Info for Diversified

According to the Spanish investor forums the meeting is today. It’s extremely difficult to translate. The volume is extremely high, it is suggest that the meeting will continue until a decision is made.

It’s progress, and completely under the radar in the UK.

https://twitter.com/pullinger_james/status/1360159260999639041?s=21

What they don’t tell you is that the RSI has been overbought since the 4th January, in that time the share price has gone from 47.75 to where it is today.

A chart cannot account for background buying off the book, or key news catalysts that will drive the share price. In this case the PD-L1 assay and large Pharma contract followed by all the other key news to come.

Just look at those companies that had 10 bagged last year and had been overbought for months, it makes no difference to investors who judge a company on its ability to meet its corporate objectives.

Many starting to show colors and their side of the book. Quite simply parsortix is an investment and not to be traded as the rerating still has significant legs over time.

To many key corporate catalysts to ignore between now and August.

Enjoy, investors.

Exactly my thoughts P25, which is why they have no choice but to lift the price to encourage loose stock

Foundation medicine participated in a collaboration in 2015 with Roche via a tender offer for an aggregate tender value of approximately USD 780 million. Roche also invested USD 250 million in Foundation Medicine by acquiring 5 million newly issued shares at USD 50 per share.

3 years later Roche took out the remaining shares for $2.4b, I believe in time we could see a similar deal structure with AGL.

That’s now 700k and counting at 93.1

Seeing about 500k at 93.1 and we know demand was still there at 92.6 for significant amounts. Will be interesting to see if we get any further late reported trades today and tomorrow as part of the demand.

But it’s significant for a number of reasons, not just because it’s good to follow the money at 5 year highs. It goes to show that deeper pockets can see the true potential and are still willing to invest significant sums at this level.

Wow, that order had been filled at 93.1 to the point I was being offered 92.6 for little stock, now they have rebooted and will offer 93.1 for significant amounts of stock again.

Deep institutional pockets or strategic investor?

I will look into it, thanks

Oh I love that, I need to work towards one of those

Hi P25, How did you find that out? It’s not clear from L2 or am I missing something?

Ability to buy for less then you can sell for right now, once that supply has gone this could rise fast

At 93.1, they are filling a large order still imo. Increasingly bullish sign

Not only is their and otc listing but the accounting period has been changed to suit U.S. reporting schedules. PWC may also be a sign.

They will pull the trigger this year imo

22nd Feb is 150 days

One product company?

Lab services - not subject to FDA approval
Pharma assays - multi billion dollar opportunities
Research based revenue - high single digit
Parsortix cassette - product sales

They all come back to the parsortix cassette but their are opportunities over and above FDA approval.

While FDA is a catalyst to HIGHER revenue, AGL are not a binary bet.

Show me a company that has been sold off on FDA approval with a similar market cap?

100% it’s not without risk, but that why the returns ahead can be so high. Thus risk v reward

Mxct has £30m revenue odd, and is valued at over £700m. Fantastic company valued on forward earnings potential.

My point being that their are liquid biopsy business's worth billions without revenue and/or minimal revue and that £196m market cap doesn’t reflect the forward revenue potential over the next 2/4 years that other companies market caps are factoring in.

Our Nasdaq listing should close this gap, but then I’m just a shareholder who hasn’t banked profits yet and I could still be wrong.

Foundation medicine was taken out for over 2 billion to, just to name one that has been subject to M&A, early stage at point of transaction.

Diagnostic companies are keen to replace Covid revenue with the large profits generated, my opinion, one of those areas will be liquid biopsy.

Well done on your profits moonP.

To add that many would of sold and traded AVCT from 10p and NCYT from 15p to name but a few multi baggers.

While it takes guts to hold onto paper profits, their is nothing wrong in banking a profit.

We are seeing again today, serious 10/15/20/30k chunks being bought at 91/92p. These shareholders will have higher targets than those at 40p, it’s all part of the process.

Exciting times, and let’s hope patience is rewarded

Guardant health - $16b
Exact sciences - $25b
Illumina - $65b
Natera inc - $10b
Labcorp - $22b

This is just a few of our peers market caps, none of which have the capacity or are approaching FDA approval to harvest live ctc cells for RNA and protein expression.

This is a $140b p.a US opportunity only. I won’t list all the near term catalysts today as I posted them yesterday and the vast majority are aware of the near term multi billion dollar opportunities that lie ahead.

FDA approval worth 20/30% from today’s £196m market cap. If that’s the case I sell all my worldly possessions and I’m all in.

If AGL achieve all that it intends to over the next 12 months, this becomes a billion pound plus company imo.